Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galinpepimut S - SELLAS Life Sciences Group

Next Previous
Drug Profile

Galinpepimut S - SELLAS Life Sciences Group

Alternative Names: 3D-189; FPI-01; GPS-Memorial-Sloan-Kettering-Cancer-Center/Sellas-Life-Sciences-Group; SLS-001; WT-1 analog peptide vaccine-Memorial-Sloan-Kettering; WT-1-analogue-peptide-vaccine-Memorial-Sloan-Kettering; WT1 cancer vaccine - SELLAS Life Sciences; WT1 peptide vaccine - Memorial Sloan Kettering; WT1 vaccine - Memorial Sloan Kettering; WT1-cancer-vaccine-Memorial-Sloan-Kettering; WT1-peptide-vaccine-Sellas-Life-Sciences-Group; ZELTHERVA

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer 3D Medicines; Bristol-Myers Squibb; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme Corp.; Sellas Life Sciences Group
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant-mesothelioma; Acute myeloid leukaemia; Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Cancer; Malignant-mesothelioma; Multiple myeloma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Haematological malignancies
  • No development reported Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Second-line therapy or greater) in USA (SC, Injection)
  • 28 May 2025 No recent reports of development identified for phase-I development in Peritoneal-cancer(Combination therapy, Second-line therapy or greater) in USA (SC, Injection)
  • 23 Jan 2025 Sellas Life Sciences announces intention to submit BLA for Acute myeloid leukemia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top